



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Center - WO66-G609
Silver Spring, MD 20993-0002

September 20, 2017

Wilson-Cook Medical, Inc.
Tiffany A. Thomas
Global Regulatory Affairs Specialist
4900 Bethania Station Road
Winston-Salem, NC 27105

Re: K170292
Trade/Device Name: Tri-Ex Extraction Balloon With Multiple Sizing
Regulation Number: 21 CFR 876.5010
Regulation Name: Biliary Catheter and Accessories
Regulatory Class: II
Product Code: GCA
Dated: August 18, 2017
Received: August 21, 2017

Dear Tiffany A. Thomas:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.

You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education (DICE) at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

<http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

<http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education (DICE) at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

<http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely,

Joyce M. Whang -S

for Benjamin R. Fisher, Ph.D.
Director
Division of Reproductive, Gastro-Renal,
and Urological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)

K170292

Device Name

Tri-Ex Extraction Balloon With Multiple Sizing

Indications for Use (Describe)

This device is used for endoscopic removal of biliary stones and contrast injection.

Type of Use (Select one or both, as applicable)

☒ Prescription Use (Part 21 CFR 801 Subpart D)

☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510(k) SUMMARY

Name: Tiffany A. Thomas, Global Regulatory Affairs Specialist
Address: Wilson-Cook Medical, Inc.
 4900 Bethania Station Road, Winston-Salem NC 27105
Phone: 336-744-0157
Date: 1/30/2017

Name of Device:

Trade Name: Tri-Ex Extraction Balloon with Multiple Sizing

Common/Usual Name: Extraction Balloon

Classification Name: Catheter, Biliary Surgical

21 CFR 876.5010, GCA, Class II

Predicate Device: Wilson-Cook Tri-Ex Extraction Balloon with Multiple Sizing,
 K040129, 02/27/2004

Intended Use

This device is used for endoscopic removal of biliary stones and for contrast injection.

Device Description:

The subject extraction balloon is comprised of a latex balloon mounted at the distal end of a nylon catheter with three internal lumens. The balloon can be inflated to three sizes, 8.5 mm, 12 mm and 15 mm diameters. Radiopaque bands placed at the distal and proximal ends of the balloon provide fluoroscopic visualization of the balloon location. The catheter length is 275 cm with a diameter of 6.6 Fr. The three lumens corresponds to a balloon inflation port, a wire guide port and an injection port. The hubs on the respective lumens are color-coded white, purple, and gray. A stopcock is included at the proximal end of the balloon inflation port to control air movement into or out of the balloon.

Substantial Equivalence:

Minor design changes were made to the predicate Wilson-Cook Tri-Ex Extraction Balloon with Multiple sizing cleared to market via K040129. These changes include dimensional changes (catheter length and diameter) and the removal of wire guide access ports. The subject extraction balloon is equivalent to the predicate device with respect to intended use, technological characteristics, and materials.

Performance Data:

A Risk Analysis was completed to assess the impact of modifications made to the cleared device using the Design Failure Modes, Effects and Criticality Analysis (DFMECA) method.

Design verification and validation testing was performed as a result of the risk analysis assessment.

Results from design validation and verification testing provide reasonable assurance that the modifications to the device do not raise any new questions of safety or effectiveness.

Summary on Non-Clinical Testing:

The following performance testing was conducted to demonstrate the basic performance of the subject device and confirmed that the subject device performs as intended.

- Balloon Diameter
- Balloon Deflation
- Balloon Strength

- Shelf Life Testing
- Packaging Validation

Biocompatibility testing was performed in accordance with the FDA Guidance, Use of International Standard ISO 10993-1, “Biological evaluation of medical devices-Part 1: Evaluation and testing within a risk management process” and per ISO 10993-1:2009, *Biological evaluation of medical devices- Evaluation and testing within risk management process*.

Conclusions:

We believe that the subject device is substantially equivalent to the predicate device in terms of intended use, key operating principles, materials and technological characteristics. We believe the risks associated with the modifications to the subject device have been adequately addressed through our Design Control Processes and do not affect safety or effectiveness of the device.